366 related articles for article (PubMed ID: 34120621)
1. Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
Sun M; Tang C; Liu J; Jiang W; Yu H; Dong F; Huang C; Rixiati Y
BMC Cancer; 2021 Jun; 21(1):696. PubMed ID: 34120621
[TBL] [Abstract][Full Text] [Related]
2. Favorable prognostic value of SOCS2 and IGF-I in breast cancer.
Haffner MC; Petridou B; Peyrat JP; Révillion F; Müller-Holzner E; Daxenbichler G; Marth C; Doppler W
BMC Cancer; 2007 Jul; 7():136. PubMed ID: 17651480
[TBL] [Abstract][Full Text] [Related]
3. Mining the prognostic significance and immune infiltration of
Zhou Y; Jiang S; Yu S; Zhu L; Liu Y; Li S; Hao N; Ren Y
Gland Surg; 2022 Apr; 11(4):720-741. PubMed ID: 35531108
[TBL] [Abstract][Full Text] [Related]
4. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
[TBL] [Abstract][Full Text] [Related]
5. Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer.
Ghafouri-Fard S; Oskooei VK; Azari I; Taheri M
World J Surg Oncol; 2018 Nov; 16(1):226. PubMed ID: 30453988
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma.
Li C; Zhang W; Fang T; Li N; Wang Y; He L; He H
Front Mol Biosci; 2021; 8():585000. PubMed ID: 34926570
[No Abstract] [Full Text] [Related]
7. SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.
Dai L; Tao Y; Shi Z; Liang W; Hu W; Xing Z; Zhou S; Guo X; Fu X; Wang X
Front Oncol; 2022; 12():881801. PubMed ID: 35600392
[TBL] [Abstract][Full Text] [Related]
8. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.
Evans MK; Yu CR; Lohani A; Mahdi RM; Liu X; Trzeciak AR; Egwuagu CE
Oncogene; 2007 Mar; 26(13):1941-8. PubMed ID: 17001312
[TBL] [Abstract][Full Text] [Related]
9. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.
Sasi W; Jiang WG; Sharma A; Mokbel K
BMC Cancer; 2010 Apr; 10():178. PubMed ID: 20433750
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer.
Fan J; Zhang Z; Chen D; Chen H; Yuan W; Zhou L; Xu J; Liu W; Xu Y
Transl Cancer Res; 2021 May; 10(5):2286-2304. PubMed ID: 35116546
[TBL] [Abstract][Full Text] [Related]
11. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities.
Song MM; Shuai K
J Biol Chem; 1998 Dec; 273(52):35056-62. PubMed ID: 9857039
[TBL] [Abstract][Full Text] [Related]
12. Identification of SOCS family members with prognostic values in human ovarian cancer.
Yang M; Chen H; Zhou L; Huang X; Su F; Wang P
Am J Transl Res; 2020; 12(5):1824-1838. PubMed ID: 32509179
[TBL] [Abstract][Full Text] [Related]
13. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the value of RAB family genes in prognosis of breast invasive carcinoma.
Lin S; Cao C; Meng Y; Wu P; Gao P; Zhi W; Peng T; Wu P; Gui L
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32432324
[TBL] [Abstract][Full Text] [Related]
15. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma.
Ying M; Li D; Yang L; Wang M; Wang N; Chen Y; He M; Wang Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1617-26. PubMed ID: 20155426
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the PTPN13 expression and its clinical implication in breast cancer.
Li JP; Zhang XM; Liu BC; Ren SG; Zhao XH; Liu YJ
Neoplasma; 2023 Apr; 70(2):188-198. PubMed ID: 36812232
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a novel zinc finger protein-related gene-based prognostic model for breast cancer.
Ye M; Li L; Liu D; Wang Q; Zhang Y; Zhang J
PeerJ; 2021; 9():e12276. PubMed ID: 34721975
[TBL] [Abstract][Full Text] [Related]
18. The expression landscape of FOXP3 and its prognostic value in breast cancer.
Li J; Zhang X; Liu B; Shi C; Ma X; Ren S; Zhao X; Liu Y
Ann Transl Med; 2022 Jul; 10(14):801. PubMed ID: 35965804
[TBL] [Abstract][Full Text] [Related]
19. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.
Tannahill GM; Elliott J; Barry AC; Hibbert L; Cacalano NA; Johnston JA
Mol Cell Biol; 2005 Oct; 25(20):9115-26. PubMed ID: 16199887
[TBL] [Abstract][Full Text] [Related]
20. Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
Chen H; Liu Y; Yin Z; Chen H; Wang Y; Qian Y
Cell Cycle; 2023 May; 22(9):1077-1100. PubMed ID: 36757135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
